OOIR: Observatory of International Research

Papers

(The H4-Index of Neuro-Oncology is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary	4745
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	1162
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	825
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019	457
EANO guideline on the diagnosis and management of meningiomas	247
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter	175
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial	153
Epidemiology of brain metastases and leptomeningeal disease	132
Fully automated hybrid approach to predict theIDHmutation status of gliomas via deep learning and radiomics	119
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling	113
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas	111
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications	111
Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma	101
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	101
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis	98
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial	90
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma	85
Associations of meningioma molecular subgroup and tumor recurrence	85
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR	78
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group	77
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification	77
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons	76
A molecularly integrated grade for meningioma	75
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study	72
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors	72

Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance	70
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors	66
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)	66
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery	66
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults	65
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors	64
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)	64
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity	62
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma	61
Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas	61
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank	61
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group	60
Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas	60
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein	59
Brain metastasis detection using machine learning: a systematic review and meta-analysis	59
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020	59
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification	58
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors	58
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases	58
Artificial intelligence neuropathologist for glioma classification using deep learning on hematoxylin and eosin stained slide images and molecular markers	58
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design	57
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study	55
A serum-based DNA methylation assay provides accurate detection of glioma	54
Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma	53
The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions	52
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes	52
TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT	51
MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry	51